Researchers have been able to mobilize the brain’s native stem cells to replenish a type of neuron lost in Huntington’s disease.
In the study, which appears today in the journal Cell Stem Cell, the scientists were able to both trigger the production of new neurons in mice with the disease and show that the new cells successfully integrated into the brain’s existing neural networks, dramatically extending the survival of the treated mice.
“This study demonstrates the feasibility of a completely new concept to treat Huntington’s disease, by recruiting the brain’s endogenous neural stem cells to regenerate cells lost to the disease,” said University of Rochester Medical Center (URMC) neurologist Steve Goldman, M.D., Ph.D., co-director of Rochester’s Center for Translational Neuromedicine.
Huntington’s disease is an inherited neurodegenerative disease characterized by the loss of a specific cell type called the medium spiny neuron, a cell that is critical to motor control. The disease, which affects some 30,000 people in the U.S., results in involuntary movements, problems with coordination, and, ultimately, in cognitive decline and depression. There is currently no way to slow or modify this fatal disease.
For Goldman, the idea behind his strategy to treat the disease emerged from his decades-long study of neural plasticity in canaries. Songbirds like canaries have intrigued biologists because of their ability — unique in the animal kingdom — to lay down new neurons in the adult brain. This process, called adult neurogenesis, was first discovered by Goldman and Fernando Nottebohm of the Rockefeller University in the early 1980s, when the two realized that when learning new songs new neurons were added to regions of the bird’s brain responsible for vocal control.
“Our work with canaries essentially provided us with the information we needed to understand how to add new neurons to adult brain tissue,” said Goldman. “Once we mastered how this happened in birds, we set about how to replicate the process in the adult mammalian brain.”
Humans already possess the ability to create new neurons. Goldman’s lab demonstrated in the 1990s that a font of neuronal precursor cells exist in the lining of the ventricles, structures found in the core of the human brain. In early development, these cells are actively producing neurons. However, shortly after birth the neural stem cells stop generating neurons and instead produce glia, a family of support cells that pervade the central nervous system. Some parts of the human brain continue to produce neurons into adulthood, the most prominent example is the hippocampus where memories are formed and stored. But in the striatum, the region of the brain that is devastated by Huntington’s disease, this capability is “switched off” in adulthood.
Goldman and his team spent the past decade attempting to unravel the precise chemical signaling responsible for instructing neural stem cells when to create neurons and when to create glia cells. One of the most critical clues came directly from the earlier research with canaries. In the part of the bird’s brain were new songs are acquired and neurons added, the scientists observed the regulated expression of a protein called brain derived neurotrophic factor, or BDNF. When the production of this protein is triggered, the local neural stem cells are instructed to produce neurons.
At the same time, the scientists also realized that they had to simultaneously suppress the bias of these stem cells to produce glia. They found that when BDNF was combined with another molecule called noggin — a protein that inhibits the chemical pathway that dictates the creation of glial cells — they could successfully switch the stem cell’s molecular machinery over to the production of neurons.
The next challenge was how to deliver these two proteins — BDNF and noggin — precisely and in a sustained fashion to the area of the brain involved in Huntington’s disease. To do so, they partnered with scientists at the University of Iowa to modify a viral gene therapeutic, called an adeno-associated virus, to deliver the necessary molecular instructions to the neural stem cells.
The virus infected the target cells in the brains of mice with Huntington’s disease and triggered the sustained over-expression of both BDNF and noggin. This, in turn, activated the neighboring neural stem cells which began to produce medium spiny motor neurons. The new neurons were continuously generated and migrated to the striatum, the region of the brain impacted by Huntington’s disease, where they then integrated into the existing neuronal networks.
The researchers were able to significantly extend the survival of the treated mice, in some cases doubling their life expectancy.
The Latest Bing News on:
Huntington’s Disease
- Best organic CBG oil: benefits, side effects, and 4 products we loveon April 25, 2024 at 12:00 pm
Curious about CBG? Learn all you need to know about the cannabinoid and see the best organic CBG oil on the market.
- Walkers needed for Huntington's disease 'Team Hope Walk' in Athenson April 25, 2024 at 10:37 am
The Georgia Chapter of the Huntington’s Disease Society of America is hosting a Team Hope Walk in Athens on Saturday.
- Indian-Origin Researcher Unravels Link Between Depression And Heart Diseaseon April 25, 2024 at 12:48 am
Depression and cardiovascular disease (CVD) partly develop from the same gene module, said a team of researchers establish ...
- Nanomaterial that mimics proteins could be basis for new neurodegenerative disease treatmentson April 24, 2024 at 5:00 pm
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases. The nanomaterial alters the interaction ...
- Jersey woman with Huntington’s completes marathonon April 22, 2024 at 4:18 am
A Jersey woman with Huntington’s disease has completed the London Marathon. Ashley Delgado, 35, ran the course to raise money and awareness for Huntington's Disease Association (HDA). Ms Delgado - who ...
- “Hope we’re going to make a difference,” Walk for Huntington’s Disease to be held in Jacksonon April 19, 2024 at 7:44 pm
The Team Hope Walk to raise funds and awareness for Huntington’s Disease is taking place at 9 a.m. at Jackson City Park on April 20 ...
- Team Home Walk for Huntington's Disease tomorrow in Jacksonon April 19, 2024 at 5:20 pm
Members of Catholic Charities of Southern Missouri hosted a ribbon cutting Thursday for its second LifeHouse Crisis Maternity Home in Cape Girardeau. Officers were called around 10 p.m. to the 2800 ...
- Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Dataon April 17, 2024 at 9:42 am
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.
- Sage halts trials in Parkinson’s after drug fails to show benefiton April 17, 2024 at 8:56 am
The Cambridge company's experimental drug was being evaluated in a Phase 2 study in people with mild cognitive impairment in Parkinson’s disease.
- Reyna’s Tacos to return to help child with rare disease — what you can doon April 17, 2024 at 8:00 am
The family of a 4-year-old San Angelo girl diagnosed with a rare neurological disease is raising funds to pay for a trip to an international conference. Here's how you can help — and walk away with a ...
The Latest Google Headlines on:
Huntington’s Disease
[google_news title=”” keyword=”Huntington’s Disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Huntington’s disease treatment
- Neurocrine: Success Continues To Roll In With Positive MDD Treatment Dataon April 25, 2024 at 3:28 pm
Neurocrine achieved positive results achieved from phase 2 SAVITRI study for the treatment of patients with MDD. Check out why NBIX stock is a strong buy.
- Link between depression and heart disease? An Indian researcher finds outon April 25, 2024 at 12:22 am
Depression and cardiovascular disease (CVD) partly develop from the same gene module, said a team of researchers establishing the long-presumed link between the ...
- Link between depression and cardiovascular disease explained: They partly develop from same gene moduleon April 24, 2024 at 9:20 pm
For example, people with depression run a greater risk of CVD, while effective early treatment for depression cuts the ... Parkinson's, and Huntington's disease. "We can use the genes in this module ...
- Nanomaterial that mimics proteins could be basis for new neurodegenerative disease treatmentson April 24, 2024 at 5:00 pm
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer's and other neurodegenerative diseases. The nanomaterial alters the interaction ...
- Anosognosia: Everything You Need to Knowon April 23, 2024 at 11:18 am
Anosognosia is a symptom in which someone lacks insight or awareness about their medical condition. It can prevent someone from recognizing they need treatment, worsening recovery outcomes. The same ...
- PTC Therapeutics gets grant for treatment of huntington’s disease using compound of formula (IBBL)on April 22, 2024 at 5:22 am
Discover the latest patent from PTC Therapeutics Inc for treating Huntington's disease with innovative compounds and pharmaceutical compositions. Learn more about the groundbreaking Formula (I) and ...
- Jersey woman with Huntington’s completes marathonon April 22, 2024 at 4:18 am
A Jersey woman with Huntington’s disease has completed the London Marathon. Ashley Delgado, 35, ran the course to raise money and awareness for Huntington's Disease Association (HDA). Ms Delgado - who ...
- Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Dataon April 17, 2024 at 9:42 am
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.
- Sage Therapeutics scraps plans for Parkinson's drug after mid-stage failureon April 17, 2024 at 7:35 am
Sage Therapeutics said on Wednesday it would stop working on its experimental drug for Parkinson's disease after the treatment failed a mid-stage study, sending the company's shares to a record low in ...
- Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flopon April 17, 2024 at 7:19 am
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment ...
The Latest Google Headlines on:
Huntington’s disease treatment
[google_news title=”” keyword=”Huntington’s disease treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]